Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical Corp is projected to achieve Surgical Aesthetics revenue in the range of $43 million to $45 million, representing a year-over-year growth of 14% at the midpoint, supported by improved operational execution and rising demand trends. The company's management has raised its full-year revenue guidance to $50.5 million to $52.5 million, indicating confidence in continued growth driven by the Surgical Aesthetics segment. Additionally, the launch of the AYON product and the increasing adoption of GLP-1 weight-loss drugs, which lead to greater demand for skin tightening procedures, are expected to contribute positively to future revenue estimates, with FY2026 now projected at $58 million.

Bears say

Apyx Medical Corp faces challenges evidenced by a projected decline in OEM sales, expected to be around $7.5 million, down from prior guidance of $8.0 million, reflecting reduced sales volumes to key existing customers. The company has also encountered sustained downward pressure on its stock price since peaking at $17.40 in September 2021, influenced by the lingering effects of an FDA warning letter and rising competition from GLP-1 medications. Additionally, Apyx reported a decrease in cash and cash equivalents, falling from $29.3 million at the end of Q2 2025 to $25.1 million at the end of Q3 2025, indicating potential liquidity concerns amid ongoing volatility in its primary revenue-generating segment.

APYX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.